The FCGR3A-158FF variant was associated with better response to anti-TNF medication at 6 weeks of treatment in a study with 35 American patients diagnosed with psoriatic pathology (n = 5) and rheumatoid arthritis (n = 30) (47.8% vs. 0%; p < 0.01) [102]. Here, TNF is linked to rheumatoid arthritis.